Private equity firm Thoma Bravo is weighing strategic options for Imprivata, including a potential sale or initial public offering, in a process that could value the healthcare-focused identity and access management company at up to $7 billion.
Thoma Bravo has engaged JPMorgan and Evercore as advisers for what has been described as an exploratory review. Possible outcomes under consideration include a sale to another buyer or a public listing, though no final decision has been announced.
Imprivata is a major provider of identity and access management technology for healthcare environments, with products designed to support single sign-on, identity assurance, and privileged access in regulated clinical settings. Its tools are widely used to help clinicians access electronic health records and other systems while meeting requirements for strong authentication, auditability, and fast user switching, including controls aimed at reducing password fatigue.
A transaction at the reported valuation would represent an increase from Thoma Bravo’s 2022 acquisition of Imprivata, which was completed at an enterprise value of roughly $5.9 billion. Any ownership change would be closely watched by healthcare providers and partners that rely on Imprivata’s product roadmap for authentication, workflow integration, and security controls, particularly as health systems balance modernization initiatives against constrained budgets.
In recent years, Imprivata has expanded its identity portfolio beyond traditional access management. The company’s face-based patient ID launch marked a move into patient identity matching, while developments such as bringing OneSign and Confirm ID to Microsoft Azure highlighted a broader push toward cloud delivery and platform integration.
The company has also pursued acquisitions to extend its capabilities. The SecureLink acquisition added tools focused on third-party access and remote connectivity, and Imprivata has previously explored biometric authentication options, including a contactless palm vein scanning partnership aimed at touchless workflows in clinical environments.
For the broader digital identity market, a potential Imprivata transaction would serve as another indicator of investor appetite for security and identity platforms serving healthcare, where regulatory obligations and ransomware risk continue to drive demand for stronger access controls across clinical and vendor-facing systems.
Sources: Yahoo Finance, Imprivata, Thoma Bravo
–
By the ID Tech Editorial Team
